Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

Lancet

Volumn 352, Issue 9139, 1998, Pages 1498-1504

  Ebers, G C ^a,x   Rice, G ^a   Lesaux, J ^a   Paty, D ^b,x   Oger, J ^b   Li, D K B ^b,b   Beall, S ^b   Devonshire, V ^b   Hashimoto, S ^b   Hooge, J ^b   Kastrukoff, L ^b   Krieger, C ^b   Mezei, M ^b   Seland, P ^b   Vorobeychi, G ^b   Morrison, W ^b   Nelson, J ^b   Freedman, M S ^c   Chrisie, S ^c   Nelson, R ^c   Rabinovitch, H ^c   Freedman, C ^c   Hartung, H P ^d   Rieckmann, P ^d   Archelos, J ^d   Jung, S ^d   Weilbach, F ^d   Flachenecke, P ^d   Sauer, J ^d   Hommes, O ^e,x,x   Jongen, P ^e   Brouwer, S ^e   McLeod, J ^f   Pollard, J ^f   Ng, R ^f   Sandberg Wollheim, M ^g,x,x   Kallen K ^g   Nilsson, P ^g   Ekberg, R ^g   Lundgren, A ^g   Jadback G ^g   Wikstrom J ^h   Multanen, J ^h   Valjakka, M ^h   Carton, H ⁱ   Lissoir, F ⁱ   Declerq, I ⁱ   Vieren, M ⁱ   Peeters, E ⁱ   Dubois, B ⁱ   Dekeersmaeker, E ⁱ   van Herle, A ⁱ   Hughes, R A C ^j,x,x   Sharrack, B ^j   Soudain, S ^j   Panelius, M ^k   Eralinna J ^k   Soilu Hanninen M ^k   Murto, S ^k   Medaer, R ^l   Broeckx, J ^l   Vanroose, E ^l   Bogaers, A ^l   Blumhardt, L D ^m   Edwards, S ^m   Liu, C ^m   Orpe, V ^m   Barnes, D ⁿ   Schwartz, M ⁿ   Stoy, N ⁿ   Harraghy, C ⁿ   Bertelsmann, F ^o   Uitdehaag, B ^o   Nasseri, K ^o   Chofflon, M ^p   Roth, S ^p   Kappos, L ^q,x   Huber, S ^q   Bellaiche, Y ^q   Senn, C ^q   King, J ^r   Joubert, J ^r   Whitten, S ^r   Newsom Davis, J M ^s   Palace, J ^s,x   Lee, M ^s   Evangelou, N ^s   Pinto, A ^s   Cavey, A ^s   Sindic, C J M ^t   Monteyne, P ^t   Verougstraete, D ^t   van Doorn, P A ^u   Moll, W ^u   Visser, L ^u   Willems, M ^u   Martina, I ^u   Buljevac, D ^u   Loman, L ^u   Bates, D ^v   Pandit, D ^v   Irving, J ^v   Rhodes, B ^b   Riddehough, A ^b   Zhao, G J ^b   Wang, X ^b   Cheng, Y ^b   Ammoury, N ^w   Dupont, F ^w   Galazka, A ^w   Hyde, R ^w   Olson, M ^w   Pernin, M O ^w   Abdul Ahad, A K ^w   Noseworthy, J ^x   Borden, E ^x   O'Brien, P ^x   Wolinsky, J ^x   more..

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^e Stichting MS Centrum   (Netherlands)

^f UNIVERSITY OF SYDNEY   (Australia)

^g LUND UNIVERSITY HOSPITAL   (Sweden)

^h HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

ⁱ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^j GUY S HOSPITAL   (United Kingdom)

^k TURKU UNIVERSITY HOSPITAL   (Finland)

^l HASSELT UNIVERSITY   (Belgium)

^m QUEEN S MEDICAL CENTRE   (United Kingdom)

ⁿ ATKINSON MORLEY S HOSPITAL   (United Kingdom)

^o VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^p GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^q UNIVERSITY HOSPITAL BASEL   (Switzerland)

^r ROYAL MELBOURNE HOSPITAL   (Australia)

^s UNIVERSITY OF OXFORD   (United Kingdom)

^t CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^u ERASMUS MEDICAL CENTER   (Netherlands)

^v ROYAL VICTORIA INFIRMARY   (United Kingdom)

^w Serono International SA   (Switzerland)

^x Ares Serono International SA ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; RECOMBINANT BETA INTERFERON;

ADULT; ANAPHYLAXIS; ARTICLE; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; FEMALE; FLU LIKE SYNDROME; HEART PALPITATION; HUMAN; INJECTION PAIN; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SEPTICEMIA; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0345601517     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)03334-0     Document Type: Article

References (37)

1. 1 Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study - I: clinical course and disability. Brain 1989; 112: 133-46.
2. 2 Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study - 2, predictive value of the early clinical course. Brain 1989; 112: 1419-28.
3. 3 Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study - 4, applications to planning and interpretation of clinical therapeutic trials. Brain 1991; 114: 1057-67.
4. 4 Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with 25 years of follow-up. Brain 1993; 116: 117-34.
5. 5 Weinshenker BG. The natural history of multiple sclerosis. Neurol Clin 1995; 13: 119-46.
6. 6 Ebers GC, Paty DW. Natural history studies and applications to clinical trials. In: Multiple sclerosis. Paty DW. Ebers GC, eds. Philadelphia: FA Davis Co, 1997: 192-228.
7. 7 Young IR, Hall AS, Pallis CA, et al. Nuclear magnetic resonance imaging of the brain in multiple sclerosis. Lancet 1981; ii: 1063-66.
8. 8 Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis-II: MRI analysis results of a multicentre, randomised, double-blind, placebo-controlled trial. Neurology 1993; 43: 662-67.
9. 9 The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45: 1277-85.
10. 10 Miller DH, Rudge P, Johnson G, et al. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain 1988; 111: 927-39.
11. 11 Miller DH, Albert PS, Barkhoff F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol 1996; 39: 6-16.
12. 12 Ebers GC. Treatment of multiple sclerosis. Lancet 1994; 343: 275-79.
13. 13 The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis - I: clinical results of a multicentre, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-61.
14. 14 Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis: the Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-94.
15. 15 Reder AT, ed. Interferon therapy of multiple sclerosis. New York: Marcel Dekker, 1997.
16. 16 Rice GPA, Ebers GC. Interferons in the treatment of multiple sclerosis: do they prevent the progression of the disease? Arch Neurol 1998 (in press).
17. 17 Thompson AJ, Noseworthy JH. New treatments for multiple sclerosis: a clinical perspective. Curr Opin Neurol 1996; 9: 187-98.
18. 18 Jacobs L, Johnson KP. A brief history of the use of interferons as treatment of multiple sclerosis. Arch Neurol 1994; 51: 1245-52.
19. 19 Simon JH, Jacobs LD, Campion M, et al. Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis. Ann Neurol 1998; 43: 79-87.
20. 20 Pozzilli C, Bastianello S, Koudriavtseva T, et al. Magnetic resonance imaging changes with recombinant human interferon-β-1a: a short-term study in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1996; 61: 251-58.
21. 21 Johnson KP, Knobler RL, Greenstein JI, et al. Recombinant human beta interferon treatment of relapsing-remitting multiple sclerosis: pilot study results. Neurology 1990; 40 (suppl 1): 261 (abstr).
22. 22 Munafo A, Trinchard-Lugan I, Nguyen TXQ, Buraglio M. Bioavailability of recombinant human interferon-β-1a after intramuscular and subcutaneous administration. Eur J Neurol 1998; 5: 187-93.
23. 23 Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
24. 24 Sandberg-Wollheim M, Hommes OR, Hughes RAC, Paty DW, Abdul-Ahad A. Recombinant human interferon beta in the treatment of relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler 1995; 1: S48-50 (abstr).
25. 25 Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
26. 26 Chernajovsky Y, Mory Y, Chen L, et al. Efficient constitutive production of human fibroblast interferon by hamster cells transformed with the IFN-β1 gene fused to an SV40 early promoter. DNA 1984; 3: 297-308.
27. 27 Schumacher GA, Beebe G, Kilber RF, et al. Problems of experimental trials of therapy in MS: report of the panel on evaluation of experimental trials in MS. Ann N Y Acad Sci 1968; 122: 552-68.
28. 28 Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis; a randomised, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983; 308: 173-80.
29. 29 Barnes D, Hughes RAC, Morris RW, et al. Randomised trial of oral and intravenous methylpredisolone in acute relapses of multiple sclerosis. Lancet 1997; 349: 902-06.
30. 30 Lui C, Li Wan Po A, Blumhardt LD. Summary measure statistic for assessing outcome of treatment trials in relapsing and remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1998; 64: 726-29.
31. 31 Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces exacerbation rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicentre, double-blind, placebo-controlled trial. Neurology 1995; 45: 1268-76.
32. 32 Ebers GC. The pathogenesis of MS. Eur J Neurol 1998; 5 (suppl 2): S7-S8.
33. 33 Goodkin DE, Cookfair D, Wende K, et al. Inter- and intrarater scoring agreement using grades 1·0 to 3·5 of the Kurtzke Expanded Disability Status Scale (EDSS): Multiple Sclerosis Collaborative Research Group. Neurology 1992; 42: 859-63.
34. 34 Noseworthy JH, Vandervoort MK, Hopkins M, Ebers GC. A referendum on clinical trial research in multiple sclerosis: the opinion of the participants at the Jekyll Island Workshop. Neurology 1989; 39: 977-81.
35. 35 Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B, for the Austrian Immunoglobulin in Multiple Sclerosis Study Group. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 1997; 349: 589-93.
36. 36 Khan OA, Dhib-Jalbut SS. Serum interferon-beta-1a (Avonex) levels following intramuscular injection in relapsing-remitting MS patients. Neurology 1998; 51: 738-42.
37. 37 The IFNS Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralising antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first 3 years. Neurology 1996; 47: 889-94.